Evidence map›Paper›PMID 21731179›Full record

Trial reportCanadian journal of veterinary research = Revue canadienne de recherche veterinaire2011

Vaccination with type III secreted proteins leads to decreased shedding in calves after experimental infection with Escherichia coli O157.

Kevin J Allen, Dragan Rogan, B Brett Finlay, Andrew A Potter, David J Asper

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Prevalence of selected Shiga toxin-producingJournal of medical microbiology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Immunoprotective Analysis of the NFA49590 Protein fromPathogens (Basel, Switzerland) · 2022
    Article
  7. Article
  8. The Role ofToxins · 2020
    Review
  9. Molecular Biology ofToxins · 2020
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kevin J AllenBioniche Life Sciences, 231 Dundas St. East, Belleville, Ontario K8N 1E2. allen12@mail.ubc.ca
Dragan Rogan
B Brett Finlay
Andrew A Potter
David J Asper

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escherichia coli O157:H7 remains a threat to humans via cattle-derived fecal contamination of food and water. Preharvest intervention strategies represent a means of reducing the pathogen burden before harvest. In this study, the efficacy of a commercially produced type III secreted protein (TTSP) vaccine was evaluated with the use of a commingled experimental calf infection model (30 placebo-treated animals and 30 vaccinates). The calves were vaccinated on days 0, 21, and 42 and infected with 10(9) colony-forming units (CFU) of E. coli O157 by oral-gastric intubation on day 56. Fecal shedding was monitored daily for 14 d. Serologic assessment revealed a robust immune response to vaccination; the serum titers of antibodies against EspA, Tir, and total TTSPs were significantly higher in the vaccinates than in the placebo-treated animals on days 21, 42, 56, and 70. Significantly less (P = 0.011) of the challenge organism was shed by the vaccinates than by the placebo-treated animals on days 3 to 10. Peak shedding occurred in both groups on days 3 to 6; during this period the vaccinates showed a mean log reduction of 1.4 (P = 0.002) and a mitigated fraction of 51%. The number of animals shedding was significantly lower among the vaccinates compared with the placebo group on days 3 to 6 (P ≤ 0.05), with a mean prevented fraction of 21%. No differences in the duration of shedding were observed. Owing to the low challenge shedding in both groups on days 11 to 14 (mean CFU/g < 10; median = 0), no significant differences were observed. These data indicate that TTSP vaccination had protective effects through significant reductions in the number of animals shedding and the number of challenge organisms shed per animal and provides evidence that TTSP vaccination is an effective preharvest intervention strategy against E. coli O157.

Indexed as

Bacterial SheddingAnimalsAntibodies, BacterialCattleCattle DiseasesEscherichia coli InfectionsEscherichia coli O157Escherichia coli ProteinsEscherichia coli VaccinesFecesVaccinationAntibodies, BacterialEscherichia coli ProteinsEscherichia coli Vaccines

Identifiers

PMID21731179
PMCPMC3062931
OpenAlexW197872207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.